Preferred Health Magazine is proud to recognize Dr. Dan Briggs
as one of its esteemed Doctors of Distinction, celebrating his impactful leadership, commitment to patient-centered care, and contributions to advancing the field of regenerative medicine.
As President and Chief Executive Officer of Auragens, Dr. Briggs has established himself as a transformative figure in modern healthcare, guiding an organization that is redefining how advanced therapies are developed, delivered, and experienced. His work has been instrumental in advancing the clinical application of mesenchymal stem cell therapies, with a focus on addressing unmet medical needs and improving outcomes for patients seeking alternatives beyond traditional care models.
Under his direction, Auragens has emerged as a leader in integrating scientific precision with a highly personalized approach to treatment. Dr. Briggs has championed rigorous standards in biologics development, prioritizing safety, quality, and transparency, principles that continue to shape the company’s reputation in an evolving and often complex sector of medicine.
In parallel, his leadership in diagnostics through MDX Labs reflects a broader commitment to strengthening the infrastructure of modern healthcare. By supporting accurate, high-quality diagnostic capabilities, Dr. Briggs has contributed to more informed clinical decision-making and enhanced patient care pathways.
Equally significant is his work expanding access to care through The Neighborhood Clinic, an initiative designed to bring essential medical services to underserved populations and a focus on health equity. This effort underscores a core tenet of his philosophy: that innovation in healthcare must be paired with accessibility and compassion to create meaningful, lasting impact.
Dr. Briggs’ influence extends beyond individual organizations. He has become a leading, and sought after voice, in advocating for thoughtful advancement within regenerative medicine, encouraging both innovation and accountability as the field continues to evolve.
Beyond business, Dr. Briggs remains deeply committed to civic and philanthropic initiatives. He serves on the Board of Directors as Treasurer for the animal advocacy group, Born Free USA, and on the Board of Trustees at the University of Northwestern Ohio, among numerous other charitable and advisory positions. His visionary leadership and impact have earned him multiple accolades, including Healthcare Executive of the Year in Nevada, CEO of the Year, and the Ernst & Young Entrepreneur of The Year.
Through a combination of visionary leadership, operational discipline, and an unwavering focus on improving life for all he touches, Dr. Briggs continues to shape a more caring and empathetic world. His recognition as a Doctor of Distinction reflects not only his professional achievements, but also his enduring commitment to improving lives through innovation in medicine and beyond.
PHM: Regenerative medicine has become one of the most rapidly evolving and closely watched areas in healthcare. As someone leading innovation in mesenchymal stem cell therapies through Auragens, how do you balance the excitement surrounding these advancements with the responsibility of maintaining scientific rigor, patient safety, and ethical accountability in such a complex field?
Dr. Dan Briggs: Look, regenerative medicine is having its moment—and rightfully so. The science is real, the outcomes are compelling, and the potential is enormous. But let’s not confuse momentum with maturity.
At Auragens, we operate with a very simple philosophy: just because you can do something doesn’t mean you should—and if you’re going to do it, you better do it right. That means obsessing over cell quality, sourcing, manufacturing standards, and clinical protocols. It means aligning with globally recognized frameworks like AABB standards, implementing IRB oversight, and demanding third-party validation wherever possible.
There’s a lot of noise in this space—bad actors, overstated claims, shortcuts disguised as innovation. We’ve made a very intentional decision to be the counterbalance to that. Science first. Patient safety always. And ethics not as a talking point, but as an operating system.
Excitement is great. Discipline is better. We choose both—but in that order.
PHM: Your work spans regenerative medicine, diagnostics, and healthcare accessibility—three areas that are fundamentally reshaping the future of patient care. How do you see these sectors converging over the next decade, and what role do you believe personalized medicine will play in transforming how physicians approach treatment and prevention?
Dr. Briggs: What we’re watching right now is the collapse of silos in healthcare. Diagnostics used to tell you what was wrong. Regenerative medicine is now starting to do something about it. And accessibility—if done right—ensures that this isn’t just reserved for the top 1%.
Over the next decade, these fields are going to fuse into a far more intelligent, responsive system. Diagnostics will become predictive, not reactive. Regenerative therapies will become more targeted, protocol-driven, and personalized. And delivery models—whether through international centers like Auragens or domestic clinics like The Neighborhood Clinic—will evolve to meet patients where they are.
Personalized medicine is the backbone of all of this. Not the buzzword version—the real version. Understanding a patient’s biology, inflammation profile, genetic predispositions, and then tailoring interventions accordingly. That’s where this goes. The future physician isn’t just diagnosing disease. They’re managing trajectory. And that’s a very different job.
PHM: Through initiatives like The Neighborhood Clinic, you’ve emphasized that healthcare innovation must also include accessibility and compassion. What have your experiences taught you about the healthcare disparities facing underserved communities, and how can leaders in medicine and business work together to create more equitable systems of care?
Dr. Briggs: The Neighborhood Clinic has been one of the most humbling—and frankly, eye-opening—experiences of my career.
When you step into underserved communities, you quickly realize the problem isn’t just access—it’s continuity, education, trust, and infrastructure. These patients aren’t “hard to reach.” The system has just never been designed to reach them properly.
We’ve seen patients who haven’t had consistent care in years. Chronic conditions unmanaged. Preventable issues turned catastrophic. Not because people don’t care—but because the system hasn’t shown up for them.
The solution isn’t charity. It’s intelligent design. And it’s removing the middleman from the equation whether that is insurance companies, pharma, or lax regulatory protections.
We need models that blend private innovation with nonprofit execution. Business leaders bring scalability, efficiency, and capital. Medical leaders bring standards, ethics, and care delivery. When those two actually collaborate—rather than operate in parallel—you can build systems that are both sustainable and compassionate.
Access without quality is dangerous. Quality without access is meaningless. You need both.
PHM: As both a healthcare executive and entrepreneur, you’ve built organizations that operate at the intersection of medicine, technology, and patient experience. What leadership principles have guided you through periods of rapid growth and industry change, and how do you foster a culture that encourages innovation while staying grounded in patient-centered values?
Dr. Briggs: I’ve always believed that culture isn’t what you say—it’s what you tolerate.
As I have grown my companies, the guiding principles have stayed consistent: trust, transparency, excellence, expertise, and education. Not as posters on a wall—but as decision-making filters.
In high-growth environments, things move fast. That’s when standards tend to slip—unless you’re intentional about protecting them. We’ve built systems, SOPs, and accountability structures that allow us to scale without diluting what makes us effective.
At the same time, innovation has to be encouraged—deliberately. I want people challenging assumptions, improving processes, asking better questions. But it has to happen within a framework that prioritizes patient outcomes above everything else. We’re not in the business of being flashy. We’re in the business of being right. And when you get that right consistently, growth tends to follow.
PHM: Preferred Health Magazine recently honored you with its prestigious Doctors of Distinction Award, recognizing your leadership, innovation, and commitment to advancing patient-centered care. What does this recognition mean to you personally and professionally, and how does it reflect the larger mission and impact you hope to continue creating through your work?
Dr.Briggs: Being recognized by Preferred Health Magazine as a Doctor of Distinction is something I’m genuinely grateful for. It reflects the work our teams are doing across the country and the Americas. And more importantly, it validates that the model we’re building— this blend of innovation, rigor, and patient-first care—is resonating. But I don’t view it as a finish line. If anything, it raises the bar.
Professionally, it reinforces that we’re on the right track. Personally, it’s a reminder of the responsibility that comes with visibility. People are paying attention—and that means we need to continue leading with integrity, not just ambition.
At the end of the day, the goal has never been recognition. It’s impact. If we can continue advancing regenerative medicine responsibly, improving diagnostic precision, and expanding access to care in a meaningful way—then that’s the real win. Everything else is just confirmation along the way.
To learn more about Dr. Dan Briggs and Auragens innovative approach to regenerative medicine, stem cell research, and longevity-focused care, visit: www.Auragens.com
Photos Courtesy Auragens
